← All trials
NCT06062238
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2024
- Primary completion
- Aug 31, 2029
- Completion date
- Aug 31, 2029
- First posted
- Oct 2, 2023
- Last posted
- Oct 2, 2023
- Enrollment
- 26000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bill and Melinda Gates FoundationLead sponsor
- Wellcome TrustCollaborator
- Bill and Melinda Gates FoundationCollaborator
- Bill and Melinda Gates FoundationStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.